These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Treatment with NMDA antagonist controls neuron death. Even in severe dementia it is not too late]. MMW Fortschr Med; 2003 Jan; 145(1-2):56. PubMed ID: 12638448 [No Abstract] [Full Text] [Related]
27. [The clinical relevance of memantine use]. Sobów T Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Bullock R Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232 [TBL] [Abstract][Full Text] [Related]
29. Memantine-related psychotic symptoms in a patient with bipolar disorder. Canan F; Ataoglu A J Clin Psychiatry; 2010 Jul; 71(7):957. PubMed ID: 20667296 [No Abstract] [Full Text] [Related]
30. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Degerman Gunnarsson M; Kilander L; Basun H; Lannfelt L Dement Geriatr Cogn Disord; 2007; 24(4):247-52. PubMed ID: 17700020 [TBL] [Abstract][Full Text] [Related]
31. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ Arch Neurol; 2006 Jan; 63(1):49-54. PubMed ID: 16401736 [TBL] [Abstract][Full Text] [Related]
32. A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). Ferris S; Schneider L; Farmer M; Kay G; Crook T Int J Geriatr Psychiatry; 2007 May; 22(5):448-55. PubMed ID: 17117395 [TBL] [Abstract][Full Text] [Related]
33. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Wilkinson D; Andersen HF Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761 [TBL] [Abstract][Full Text] [Related]
34. Memantine therapy for Alzheimer disease in real-world practice: an observational study in a large representative sample of French patients. Vidal JS; Lacombe JM; Dartigues JF; Pasquier F; Robert P; Tzourio C; Alpérovitch A Alzheimer Dis Assoc Disord; 2008; 22(2):125-30. PubMed ID: 18525283 [TBL] [Abstract][Full Text] [Related]
35. Memantine (Ebixa) in clinical practice - results of an observational study. Calabrese P; Essner U; Forstl H Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714 [TBL] [Abstract][Full Text] [Related]
36. [Efficacy of memantine in the treatment of Alzheimer's disease]. Molinuevo Guix JL; Lladó Plarrumaní A Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590 [TBL] [Abstract][Full Text] [Related]
37. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Van Dam D; De Deyn PP Eur Neuropsychopharmacol; 2006 Jan; 16(1):59-69. PubMed ID: 16095884 [TBL] [Abstract][Full Text] [Related]
38. Alzheimer's disease: will advances made in the past turn the tide? Semla TP Ann Pharmacother; 2007 Sep; 41(9):1494-6. PubMed ID: 17666576 [No Abstract] [Full Text] [Related]
39. Factors affecting usage patterns of memantine in Alzheimer disease. Lerner AJ; McClendon MJ; Sami SA; Ogrocki PK; Adams KB; Smyth KA Alzheimer Dis Assoc Disord; 2008; 22(2):137-43. PubMed ID: 18525285 [TBL] [Abstract][Full Text] [Related]
40. Does memantine improve the gait of individuals with Alzheimer's disease? Beauchet O; Allali G; Launay C; Fantino B; Annweiler C J Am Geriatr Soc; 2011 Nov; 59(11):2181-2. PubMed ID: 22098042 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]